|
Information For:
|
Anti-Counterfeiting Measures and USP StandardsAdopted by the Council of Experts Executive CommitteeMarch 2008 USP works continuously and supportively with all parties who wish to combat counterfeit medicines. This activity is conducted primarily by USP management through USP's national and international public health programs. USP's standards–setting activities are directed primarily to practitioners and patients, working in concert with pharmaceutical manufacturers, pharmaceutical distributors, compounding professionals, and conformity assessment bodies such as FDA. At no time should overt anti–counterfeiting measures interrupt or otherwise distort or disturb labeling and other standards created by the Council of Experts that reflect usual and customary communications between providers and patients/consumers in achieving access to and appropriate use of good quality, safe, and, where appropriate, beneficial, food and drugs. All requests for incorporation of anti–counterfeiting measures in USP's standards-setting activities should be referred to the Council of Experts Executive Committee for discussion and, as appropriate, action. Via management, USP will work to promote anti–counterfeiting activities in the USP and elsewhere consistent with its mission. What's NewPF 35(6) Errata (10/30/09) New official Text for October: 15 Revisions Bulletins (10/30/09) PF 35(6), November-December 2009: Highlights and Stimuli Articles (10/23/09) Admission Criteria and Safety Classification for Dietary Supplements Guideline (10/22/09) Elemental Impurities Hot Topics information updated (10/13/09) General Chapter <1151> Pharmaceutical Dosage Forms (10/06/09) Heparin Hot Topics information updated (10/02/09) New Official Text for September (09/29/09) Pending Standards for the month of September (09/25/09) PF 35(5) IRAs and Errata (08/31/09)
Related Resources |
||||||||||||||||||||||||||||
Copyright © 2009 The United States Pharmacopeial Convention
|
|||||||||||||||||||||||||||||